Share-based Payment Arrangement, Expense of Co-Diagnostics, Inc. from 30 Jun 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Co-Diagnostics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2018 to 30 Sep 2025.
  • Co-Diagnostics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $500,585, a 52% decline year-over-year.
  • Co-Diagnostics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $3,274,507, a 45% decline year-over-year.
  • Co-Diagnostics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $5,434,904, a 35% decline from 2023.
  • Co-Diagnostics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $8,336,855, a 11% increase from 2022.
  • Co-Diagnostics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $7,543,223, a 37% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Co-Diagnostics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $3,274,507 $500,585 -$544,998 -52% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $3,819,505 $580,265 -$919,393 -61% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $4,738,898 $875,228 -$696,006 -44% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $5,434,904 $1,318,429 -$507,718 -28% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $5,942,622 $1,045,583 -$1,126,582 -52% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $7,069,204 $1,499,658 -$670,143 -31% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $7,739,347 $1,571,234 -$597,508 -28% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $8,336,855 $1,826,147 -$578,259 -24% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $8,915,114 $2,172,165 -$58,269 -2.6% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $8,973,383 $2,169,801 +$636,515 +42% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $8,336,868 $2,168,742 +$793,645 +58% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $7,543,223 $2,404,406 +$746,296 +45% 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 $6,796,927 $2,230,434 +$819,489 +58% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $5,977,438 $1,533,286 +$605,949 +65% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $5,371,489 $1,375,097 -$137,915 -9.1% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $5,509,404 $1,658,110 +$1,087,445 +191% 01 Oct 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
Q3 2021 $4,421,959 $1,410,945 +$367,811 +35% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $4,054,148 $927,337 +$235,918 +34% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $3,818,230 $1,513,012 +$1,080,189 +250% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $2,738,041 $570,665 -$27,511 -4.6% 01 Oct 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
Q3 2020 $2,765,552 $1,043,134 +$767,201 +278% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $1,998,351 $691,419 +$564,936 +447% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $1,433,415 $432,823 +$345,029 +393% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q4 2019 $1,088,386 $598,176 01 Oct 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
Q3 2019 $275,933 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020 2020 Q3
Q2 2019 $126,483 -$87,795 -41% 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2019 2019 Q2
Q1 2019 $87,794 01 Jan 2019 31 Mar 2019 10-Q 14 May 2019 2019 Q1
Q2 2018 $214,278 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2019 2019 Q2

Co-Diagnostics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $5,434,904 -$2,901,951 -35% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $8,336,855 +$793,632 +11% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $7,543,223 +$2,033,819 +37% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 $5,509,404 +$2,771,363 +101% 01 Jan 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
2020 $2,738,041 +$1,649,655 +152% 01 Jan 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
2019 $1,088,386 01 Jan 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.